Deconstructing p53 transcriptional networks in tumor suppression

Trends in Cell Biology

Volumn 22, Issue 2, 2012, Pages 97-106

  Bieging, Kathryn T ^a   Attardi, Laura D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBP PROTEIN; FAS ANTIGEN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45 ALPHA; HISTONE ACETYLTRANSFERASE GCN5; P53 APOPTOSIS EFFECTOR RELATED TO PMP 22; P53 INDUCED PROTEIN WITH A DEATH DOMAIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN; PROTEIN BAX; PROTEIN NOXA; PROTEIN P21; PROTEIN P300; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE RECEPTOR V; PUMA PROTEIN; TAF6 PROTEIN; TAF9 PROTEIN; TATA BINDING PROTEIN ASSOCIATED FACTOR; TRAP80 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR 10B; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; CANCER INHIBITION; CELL CYCLE ARREST; CELL METABOLISM; CELL MIGRATION; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION; GENE TARGETING; HUMAN; HYPOXIA; KNOCKOUT GENE; KNOCKOUT MOUSE; NONHUMAN; NUTRITIONAL DEFICIENCY; ONCOGENE; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SENESCENCE; TELOMERE; TUMOR MODEL;

ANIMALS; APOPTOSIS; GENE REGULATORY NETWORKS; HUMANS; NEOPLASMS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84856525447     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2011.10.006     Document Type: Review

References (95)

1. Brady C.A., Attardi L.D. p53 at a glance. J. Cell Sci. 2010, 123:2527-2532.
2. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
3. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
4. Halazonetis T.D., et al. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
5. Christophorou M.A., et al. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006, 443:214-217.
6. Efeyan A., et al. Tumour biology: policing of oncogene activity by p53. Nature 2006, 443:159.
7. Hinkal G., et al. Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS ONE 2009, 4:e6654.
8. Brosh R., Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 2009, 9:701-713.
9. Venot C., et al. Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains. Oncogene 1999, 18:2405-2410.
10. Candau R., et al. Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity. Oncogene 1997, 15:807-816.
11. Zhu J., et al. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J. Biol. Chem. 1998, 273:13030-13036.
12. Khoury M.P., Bourdon J.C. The isoforms of the p53 protein. Cold Spring Harb. Perspect. Biol. 2010, 2:a000927.
13. Maier B., et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 2004, 18:306-319.
14. Johnson T.M., et al. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat. Genet. 2005, 37:145-152.
15. Brady C.A., et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011, 145:571-583.
16. Riley T., et al. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9:402-412.
17. Smeenk L., et al. Role of p53 serine 46 in p53 target gene regulation. PLoS ONE 2011, 6:e17574.
18. Schmitt C.A., et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002, 1:289-298.
19. Xiang H., et al. Bax involvement in p53-mediated neuronal cell death. J. Neurosci. 1998, 18:1363-1373.
20. Chong M.J., et al. Atm and Bax cooperate in ionizing radiation-induced apoptosis in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:889-894.
21. Johnson M.D., et al. Evidence for involvement of Bax and p53, but not caspases, in radiation-induced cell death of cultured postnatal hippocampal neurons. J. Neurosci. Res. 1998, 54:721-733.
22. Mccurrach M.E., et al. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:2345-2349.
23. Pritchard D.M., et al. Damage-induced apoptosis in intestinal epithelia from bcl-2-null and bax-null mice: investigations of the mechanistic determinants of epithelial apoptosis in vivo. Oncogene 1999, 18:7287-7293.
24. Knudson C.M., et al. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995, 270:96-99.
25. Knudson C.M., et al. Bax accelerates tumorigenesis in p53-deficient mice. Cancer Res. 2001, 61:659-665.
26. Shibata M.A., et al. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J. 1999, 18:2692-2701.
27. Yin C., et al. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997, 385:637-640.
28. Eischen C.M., et al. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol. Cell. Biol. 2001, 21:7653-7662.
29. Dansen T.B., et al. Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo. J. Biol. Chem. 2006, 281:10890-10895.
30. Vaseva A.V., Moll U.M. The mitochondrial p53 pathway. Biochim. Biophys. Acta 2009, 1787:414-420.
31. Oda E., et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058.
32. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7:683-694.
33. Jeffers J.R., et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003, 4:321-328.
34. Villunger A., et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003, 302:1036-1038.
35. Qiu W., et al. PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell 2008, 2:576-583.
36. Michalak E.M., et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ. 2009, 16:684-696.
37. Garrison S.P., et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol. Cell. Biol. 2008, 28:5391-5402.
38. Hemann M.T., et al. Suppression of tumorigenesis by the p53 target PUMA. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:9333-9338.
39. Ploner C., et al. Noxa: at the tip of the balance between life and death. Oncogene 2008, 27(Suppl. 1):S84-S92.
40. Shibue T., et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev. 2003, 17:2233-2238.
41. Naik E., et al. Ultraviolet radiation triggers apoptosis of fibroblasts and skin keratinocytes mainly via the BH3-only protein Noxa. J. Cell Biol. 2007, 176:415-424.
42. Akhtar R.S., et al. BH3-only proapoptotic Bcl-2 family members Noxa and Puma mediate neural precursor cell death. J. Neurosci. 2006, 26:7257-7264.
43. Michalak E.M., et al. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 2008, 15:1019-1029.
44. Attardi L.D., et al. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 1996, 15:3693-3701.
45. Yu J., et al. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 2001, 7:673-682.
46. Attardi L.D., et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 2000, 14:704-718.
47. Ihrie R.A., et al. Perp is a p63-regulated gene essential for epithelial integrity. Cell 2005, 120:843-856.
48. Beaudry V.G., et al. Loss of the p53/p63 regulated desmosomal protein Perp promotes tumorigenesis. PLoS Genet. 2010, 6:e1001168.
49. Finnberg N., et al. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol. Cell. Biol. 2005, 25:2000-2013.
50. Finnberg N., et al. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J. Clin. Invest. 2008, 118:111-123.
51. Kim I.R., et al. DNA damage- and stress-induced apoptosis occurs independently of PIDD. Apoptosis 2009, 14:1039-1049.
52. Adachi M., et al. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:2131-2136.
53. Min/+ mice increases intestinal tumor burden. PLoS ONE 2010, 5:e9070.
54. Chen L., et al. CD95 promotes tumour growth. Nature 2010, 465:492-496.
55. Harper J.W., et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
56. El-Deiry W.S., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
57. Deng C., et al. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995, 82:675-684.
58. Brugarolas J., et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995, 377:552-557.
59. Pantoja C., Serrano M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 1999, 18:4974-4982.
60. Martin-Caballero J., et al. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res. 2001, 61:6234-6238.
61. Jones J.M., et al. Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Differ. 1999, 10:213-222.
62. Jackson R.J., et al. p21Cip1 nullizygosity increases tumor metastasis in irradiated mice. Cancer Res. 2003, 63:3021-3025.
63. Brugarolas J., et al. p21 is a crucial CDK2 regulator essential for proliferation control in Rb-deficient cells. J. Cell Biol. 1998, 141:503-514.
64. Cole A.M., et al. p21 loss blocks senescence following Apc loss and provokes tumourigenesis in the renal but not the intestinal epithelium. EMBO Mol. Med. 2010, 2:472-486.
65. Hollander M.C., et al. Genomic instability in Gadd45a-deficient mice. Nat. Genet. 1999, 23:176-184.
66. Hildesheim J., et al. Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer Res. 2002, 62:7305-7315.
67. 2-terminal kinase and p38 stress signaling resulting in apoptosis and senescence. Cancer Res. 2006, 66:8448-8454.
68. Tront J.S., et al. Gadd45a functions as a promoter or suppressor of breast cancer dependent on the oncogenic stress. Cancer Res. 2010, 70:9671-9681.
69. De Stanchina E., et al. PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 2004, 13:523-535.
70. Ferbeyre G., et al. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 2000, 14:2015-2027.
71. Pearson M., et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000, 406:207-210.
72. Wang Z.G., et al. Role of PML in cell growth and the retinoic acid pathway. Science 1998, 279:1547-1551.
73. Rego E.M., et al. Role of promyelocytic leukemia (PML) protein in tumor suppression. J. Exp. Med. 2001, 193:521-529.
74. Doumont G., et al. G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv. EMBO J. 2005, 24:3093-3103.
75. Liu G., et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat. Genet. 2004, 36:63-68.
76. Barboza J.A., et al. p21 delays tumor onset by preservation of chromosomal stability. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:19842-19847.
77. Jiang D., et al. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:17123-17128.
78. Kawase T., et al. PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell 2009, 136:535-550.
79. Thut C.J., et al. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 1995, 267:100-104.
80. Di Lello P., et al. Structure of the Tfb1/p53 complex: insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol. Cell 2006, 22:731-740.
81. Ferreon J.C., et al. Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6591-6596.
82. Teufel D.P., et al. Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:7009-7014.
83. Attardi L.D., Donehower L.A. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat. Res. 2005, 576:4-21.
84. Symonds H., et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994, 78:703-711.
85. Cosme-Blanco W., et al. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep. 2007, 8:497-503.
86. Dankort D., et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 2007, 21:379-384.
87. Chen Z., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
88. Ventura A., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
89. Ihrie R.A., et al. Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr. Biol. 2003, 13:1985-1990.
90. O'connor L., et al. CD95 (Fas/APO-1) and p53 signal apoptosis independently in diverse cell types. Cancer Res. 2000, 60:1217-1220.
91. Adnane J., et al. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene 2000, 19:5338-5347.
92. Dulic V., et al. Uncoupling between phenotypic senescence and cell cycle arrest in aging p21-deficient fibroblasts. Mol. Cell. Biol. 2000, 20:6741-6754.
93. Philipp J., et al. Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis. Oncogene 1999, 18:4689-4698.
94. Elyada E., et al. CKIalpha ablation highlights a critical role for p53 in invasiveness control. Nature 2011, 470:409-413.
95. Bulavin D.V., et al. Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a. Mol. Cell. Biol. 2003, 23:3859-3871.